Innovative biological insecticide for use in greenhouses / Market launch in Europe planned in 2017 / Bayer’s first active ingredient approved under regulation EC 1107/2009
Monheim, 18-8-2015 — /EuropaWire/ — Bayer CropScience has reached an important milestone towards the market introduction of its biological insecticide Requiem™ in Europe. Its active ingredient Terpenoid Blend QRD 460 has been recently approved by the European Commission. For growers and the entire food value chain, Requiem™ provides control of sucking pests and extends quality of harvested produce. First registrations of Requiem™ are expected in some European countries before end of 2016. Market launch in Europe is planned for 2017.
“Requiem™ is the latest innovation from Bayer CropScience in the field of biological insecticides and an important addition to integrated pest management (IPM) programs in greenhouse vegetables”, pointed out Gilles Chevallier, Global Product Management Biological Insecticides at Bayer CropScience. “Its mode of action is effective against sucking pests, especially thrips, whiteflies, aphids and mites, leading to healthier crops and better-quality produce.”
“We are very proud of the approval by the European Commission”, said Nick Wright, Global Regulatory Manager Biologicals at Bayer CropScience. “This is the first time a Bayer active substance gains approval under the new EU regulation 1107/2009.” The regulation was designed to ensure high level of protection of both human and animal health and the environment; while improving agricultural production. “The harmonization for the authorization of plant protection products within the EU will help us providing growers across Europe innovative tools like Requiem”, Wright added.
Requiem™ was developed to control sucking pests in a wide range of fruits and vegetables, and some row crops. Requiem™ is intended for use as foliar insecticide and acaricide – in spray programs, as a standalone or together with chemical crop protection products. In addition to its efficacy level, Requiem™ offers growers flexible use-rates and flexible application timing. It is exempt from maximum residue levels (MRLs), IPM compatible, has a short re-entry interval, and no pre-harvest interval. Furthermore, it is a valuable tool for resistance management.
Requiem™ is based on the optimized blend of terpenes intended to mimic the naturally occurring extract of the plant species Chenopodium ambrosioides near ambrosioides, a flowering plant commonly known as Epazote and American Wormseed. Bayer was able to get this blend successfully approved in the U.S. and the EU as a single active substance.
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 9,494 million (2014) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 23,100 and is represented in more than 120 countries. This and further news is available at:www.press.bayercropscience.com.
Find more information at www.bayercropscience.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.